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Abstract
Background: Melanoma is a cancer with rising incidence and new therapeutics are needed. For this, it is necessary
to understand the molecular mechanisms of melanoma development and progression. Melanoma differs from
other cancers by its ability to produce the pigment melanin via melanogenesis; this biosynthesis is essentially regulated
by microphthalmia-associated transcription factor (MITF). MITF regulates various processes such as cell cycling and
differentiation. MITF shows an ambivalent role, since high levels inhibit cell proliferation and low levels promote
invasion. Hence, well-balanced MITF homeostasis is important for the progression and spread of melanoma. Therefore,
it is difficult to use MITF itself for targeted therapy, but elucidating its complex regulation may lead to a promising
melanoma-cell specific therapy.
Method: We systematically analyzed the regulation of MITF with a novel established transcription factor based gene
regulatory network model. Starting from comparative transcriptomics analysis using data from cells originating from
nine different tumors and a melanoma cell dataset, we predicted the transcriptional regulators of MITF employing ChIP
binding information from a comprehensive set of databases. The most striking regulators were experimentally validated
by functional assays and an MITF-promoter reporter assay. Finally, we analyzed the impact of the expression of the
identified regulators on clinically relevant parameters of melanoma, i.e. the thickness of primary tumors and patient
overall survival.
Results: Our model predictions identified SOX10 and SOX5 as regulators of MITF. We experimentally confirmed the role
of the already well-known regulator SOX10. Additionally, we found that SOX5 knockdown led to MITF up-regulation in
melanoma cells, while double knockdown with SOX10 showed a rescue effect; both effects were validated by reporter
assays. Regarding clinical samples, SOX5 expression was distinctively up-regulated in metastatic compared to primary
melanoma. In contrast, survival analysis of melanoma patients with predominantly metastatic disease revealed that low
SOX5 levels were associated with a poor prognosis.
Conclusion: MITF regulation by SOX5 has been shown only in murine cells, but not yet in human melanoma cells.
SOX5 has a strong inhibitory effect on MITF expression and seems to have a decisive clinical impact on melanoma
during tumor progression.
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Normal melanocytes located in the stratum basale of
the epidermis are beneficial cells that are capable of pro-
ducing the pigment melanin; these cells transfer melanin
to keratinocytes and by this means prevent DNA dam-
age which can be caused by ultraviolet radiation. How-
ever, melanocytes can transform into malignant cells.
Melanoma cells exhibit an imbalanced regulation that al-
lows for abnormally high proliferation rates, reduced
apoptosis and the potential to form metastases. Melanoma
is the most lethal form of skin cancer and causes approxi-
mately 75 % of all skin cancer deaths, with a rising inci-
dence rate in the last three decades [1–3]. Although the
resection of early diagnosed melanoma yields very high
curation rates, for progressed melanoma, no effective ther-
apy is currently available. Common tumor treatments like
radiotherapy and chemotherapy often fail for the treat-
ment of patients with metastatic melanoma, and the aver-
age survival rate for these patients is less than 1 year [3,
4]. To improve treatment for therapy, it is mandatory to
better understand the molecular pathways and transcrip-
tional regulation involved in melanoma formation. In par-
ticular, changes in the transcriptional regulation driving
melanoma progression and metastasis are crucial to find
new strategies to cure melanoma patients [5, 6].
We focused our work on the so-called master regulator
of melanocytes and melanoma cells, microphthalmia-
associated transcription factor (MITF) [7]. MITF is a
basic-helix-loop helix leucine zipper transcription factor
that binds as a dimer to conserved sequences of the E-box
(CATGTG) and M-box (AGTCATGTGCT) motifs in the
promoter region of its target genes. MITF regulates sev-
eral genes involved in melanocyte differentiation, prolifer-
ation and it also regulates the expression of the two
pacemaker enzymes of melanogenesis, tyrosinase (TYR)
and dopachrome tautomerase (DCT) [8, 9]. Most melan-
oma cancer cells maintain their ability to produce
melanin, and often genes of melanogenesis are highly
expressed. These characteristics distinguish melanoma
cells from other cancer cells and melanogenesis is a dis-
cussed target for chemotherapy [10].
Different MITF expression levels have been shown to
result in very divergent clinical courses in melanoma pa-
tients. Low MITF expression levels can be observed in
invasive melanoma and are therefore associated with a
low survival rate [11]. On the contrary, high MITF ex-
pression levels can slow down the proliferation of mel-
anoma cells [12]. Cancer cells are characterized by an
abnormally high proliferation rate and they circumvent
cell cycle stagnancy and apoptosis. A strategy of melan-
oma cells to gain a high proliferation rate is to avoid high
MITF expression levels, which have an anti-proliferative
effect. Besides this, many melanoma tumors (~50 %) ex-
hibit a driving mutation in the serine/threonine-proteinkinase B-RRAF (BRAF) [13, 14]. The mutation results in a
constantly activated kinase that permanently stimulates
extracellular-signal regulated protein kinase 2 (ERK2),
which in turn phosphorylates and targets MITF proteins
for ubiquitin-dependent degradation via the proteasomal
pathway [15] and thereby decreases the activity of MITF.
Hoek and coworkers found that MITF levels can be used
as a marker to distinguish proliferative and invasive phe-
notypes of melanoma cell lines with low MITF levels
marking the invasive state [12, 16, 17].
The aim of this study was to further investigate the
regulation of MITF and the impact of MITF regulators
on melanoma progression. The transcriptional regula-
tion of MITF is very complex, involving numerous acti-
vating and inhibiting factors. For example, SRY (sex
determining region Y)-box 10 (SOX10), paired box 3
(PAX3) [18] and one cut homeobox 2 (ONECUT2) [19]
activate MITF expression, whereas zinc finger E-box-
binding homeobox 1 (ZEB1) [20] and GLI family zinc
finger 2 (GLI2) [21] repress MITF expression.
We applied a computational approach we developed
earlier [22] to identify MITF transcriptional regulators
that could predict changes in MITF expression levels
over a set of different cancer types (NCI-60 panel) and a
set of melanoma samples. The next step was to verify
the effect of the obtained regulators on MITF mRNA
levels using siRNA transfection and an MITF-promoter
reporter assay. Finally, we unraveled the relationships
between the obtained transcription factor expression
levels and central clinical parameters like overall survival
and the Breslow thickness.
Methods
Gene regulatory network models to identify regulators of
MITF
We developed a transcription factor (TF) MITF target
gene regulatory network model. We wanted to identify
TFs that best explain different MITF expression levels
over a set of different cell lines. For this, we predicted
the expression of the MITF gene in a sample j by min-
imizing the differences emitf,j between real MITF expres-
sion gmitf,j and predicted expression ~gmitf ;j realized by the
constraints
gmitf ;j−~gmitf ;j−emitf ;j≤0 ð1Þ
−gmitf ;j þ ~gmitf ;j−emitf ;j≤0 ð2Þ
The predicted MITF expression was based on the lin-
ear equation
~g i;j ¼ β0 þ
XT
t¼1βt ⋅est;i ⋅eff t;j ð3Þ
with an additive offset β0. T is the number of all TFs
with available information on target genes, βt is the
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from an integration of binding data in order to only ac-
count for TFs that are known or predicted to regulate
MITF. est,i is equal to or greater than 1 if we had experi-
mental and computational evidence of TF t binding to
gene i using the databases Metacore™ (http://thomson-
reuters.com/metacore/), ChEA [23], Encode (http://
www.genome.gov/Encode/) and Transcription Factor
Binding Affinity (TBA) [24] (details are given in the next
section and at [22]). efft,j is the effect of TF t in sample j
and was calculated by the activity of a TF based on its
cumulative effect on its target genes, i.e.
eff tj ¼ acttj ¼
Xn
i¼1esti⋅g ijXn
i¼1esti
ð4Þ
With the use of a branch and cut based optimization
program (Gurobi™ 5.5, http://www.gurobi.com/) to solve
the Mixed Integer Linear Programming (MILP) problem,
the β-coefficients were calculated in order to minimize
the sum of differences between measured and predicted
MITF expression for all samples (objective function).
The MITF model was restricted to a defined number of
regulators from the set of all putative regulators (19
TFs). We applied a bottom-up approach to identify the
most important regulators of the model, starting with
restricting the model to one regulator. Within each of
the following runs, one additional regulator was added
to the model. The optimizer selected independently in
every run the best regulators in order to minimize the
objective function. The prediction performance of each
model was estimated by the correlation between real
and predicted MITF expression in the test data (unseen
data, not used for learning the model) based on a leave-
one-out cross validation (LOO-CV). For details regard-
ing the MILP model and activity definition see Schacht
et al. [22].
Binding evidence
As described previously [22], we used several sources to
assess TF binding information. From the database Meta-
CoreTM (http://thomsonreuters.com/metacore/) human
TF-target gene interactions were selected, of both of the
categories direct and indirect. Additionally, we used z-
scores of the Total Binding Affinity (TBA) which are cal-
culated TF binding profiles for the whole promoter
based on position weight matrices [24, 25]. Moreover,
human entries of the CHIP Enrichment Analysis (ChEA)
database were used containing large data sets of high-
throughput chromatin immunoprecipitation experi-
ments [23]. At the date of analysis (July 2013) the ChEA
database for man comprised of 83 transcription factors,
20,035 genes and 131,996 total entries. In addition, we
used chromatin immunoprecipitation data from theENCODE project (http://www.genome.gov/Encode/). We
used binding information of cell lines for which the most
comprehensive set of regulation information was available
(Tier 1). Binding of a transcription factor to a target gene
as listed in Encode, was scored as “1” or if absent, as “0”,
respectively. Target genes occurring more than once, were
combined in single rows containing consistent (intersect-
ing) hits and transcription factors showing up multiple
times were assembled into one column as the union of
hits. Information on regulatory transcription factor/target
gene interaction was considered reliable if (i) this pair was
found in Metacore with the annotation “direct”, or if (ii)
this pair was found in at least two of the datasets Meta-
core “indirect”, CheA, Encode and TBA with a value
greater or equal to one. For these TF/target gene pairs,
their putative regulatory interaction was denoted edge
strength est,i between TF t and target gene i, and set to the
number of occurrences of the specific TF/target gene
combinations among the datasets CheA, Metacore “dir-
ect” activation, Metacore “direct inhibition”, Metacore “in-
direct activation” and Metacore “indirect inhibition”. TBA
values greater or equal to one were added to the edge
strength. For all TF/target gene pairs missing criteria (i) or
(ii), the edge strength was set to zero, i.e. this TF/target
gene pair was not considered by our prediction algo-
rithms. The binding information of SOX5/MITF inter-
action was taken from Metacore where it was annotated
as “direct inhibition”. In addition, the z-score of TBA of
SOX5 binding to the human MITF promoter was strongly
positive (z = 1.5, see Additional file 1: Figure S1).
Gene expression data
To identify prominent transcription factors of MITF
with our regulatory network model, we used the gene
expression profiles of 59 cancer cell lines from the Na-
tional Cancer Institute (NCI-60 panel), which comprises
60 cancer cell lines from nine different cancer types
(breast, central nervous system, colon, kidney, leukemia,
lung, melanoma, ovary and prostate). The data were
downloaded from CellMiner and based on an integration
of five different microarray platforms (5-Platform, Affy-
metrix HG-U95, HG-U133, HG-U133 Plus 2.0, GH
Exon 1.0 ST, and Agilent WHG) yielding a z-score for
each gene of each sample (details, see [26]). Missing
values were replaced by the mean expression values of
the according genes. The cell line SF 539 was excluded
from our analysis because of a large number (N =
10,404) of undefined entries. Subsequently, we continued
the analysis of MITF’s TFs on a second, independent data-
set, to see whether our findings are consistent and repro-
ducible. Therefore, we used gene expression data from
melanoma cells taken from a study by Hoek et al. [16, 17].
In brief, melanoma cells were released from tissue sections
of melanoma metastases. Cells were cultured, total RNA
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using Affymetrix HG-U133 plus 2.0 oligonucleotide mi-
croarrays. Raw intensity signals were normalized employ-
ing Affymetrix MAS 5.0. Values below 0.01 were set to
0.01 and each value was divided by the 50th percentile of
all values in that sample. Each expression value was di-
vided by the median of its values in all samples. Finally,
expression values were z-normalized for each gene. For
our analysis, we used expression data from 33 samples
from the Mannheim cohort of the study by Hoek and co-
workers (subsequently denoted as the Mannheim cohort).
Cell lines from this panel were also used for our in vitro
experiments. For inferring clinical and expression data, we
used skin cutaneous melanoma (SKCM) samples from the
Cancer Genome Atlas (TCGA; http://cancergenome.nih.-
gov/). Clinical as well as MITF, SOX5 and SOX10 mRNA
expression (RNA Seq V2 RSEM) data were downloaded
from the cBio portal (http://www.cbioportal.org/). The
SKCM expression data were z-normalized. For the com-
parison of expression levels between non-survived and
survived subgroups Wilcoxon rank sum tests were ap-
plied, because the distribution of the expression levels was
not normally distributed. All data sets used are publically
available.
Cell culture
Five melanoma cell lines used in the Hoek and coworkers
analysis [16, 17] MaMel-122, MaMel-86b, MaMel-61e and
MaMel-79b (own laboratory) as well as A375 purchased
from ATCC were cultured at 37 °C and 5 % CO2 in RPMI
1640 medium (Gibco, Carlsbad, CA, USA) + 10 % FCS in
general without antibiotics. MaMel-122-pMITF-GFP was
cultured in medium containing 0.5 μg/ml puromycin
(Sigma-Aldrich, Steinheim, Germany). These cell lines
were chosen because they exhibit substantial expression
of MITF, SOX5 and SOX10.
siRNA transfection and qRT-PCR
To investigate the effects of SOX5 and SOX10 on MITF
expression levels, Ambion® Silencer® Select Pre-designed
(Inventoried) siRNAs (Life Technologies, Carlsbad, CA,
USA) were utilized to knock down these transcription
factors. For the knock-down of SOX5 or SOX10 siRNA
s13303 (Antisense sequence, no overhangs: UCCUUU
CACACCGUAAGUG) and siRNA s13308 (Antisense,
no overhangs: UCCUUCUUCAGAUCGGGCU) were
used, respectively.
For validation of siRNA mediated knock-down effects
and to diminish off-target effects, defined, high com-
plexity SOX5 and control siRNA pools consisting of 30
individual siRNAs each (siTOOLs Biotech, Planegg,
Germany) [27] were included. Melanoma cells were
seeded in 12-well plates and cultured for 24 h to reach
70–80 % confluency. Transfections were performedaccording to the manufacturer’s instructions (Dharma-
Fect transfection reagent; GE Healthcare, Little Chal-
font, United Kingdom) using 25 nM single siRNAs and
10 nM for siRNA pools. Forty eight h post transfection,
cell pellets were collected and stored at -80 °C until
RNA was isolated with the miRNeasy Mini Kit (Qiagen,
Hilden, Germany) according to the manufacturer’s
protocol. Reverse transcription was performed using
the Transcriptor First Strand cDNA Synthesis Kit
(Roche Applied Science, Mannheim, Germany). 500 ng
of total RNA was reverse transcribed in a 20 μl reaction
utilizing oligo(dT) primers. The cDNA was diluted (1:5)
with PCR-quality water (Sigma-Aldrich, Steinheim,
Germany) and 2 μl of the cDNA dilution was used for
qRT-PCR in a 20 μl reaction using the TaqMan® Universal
PCR Mastermix (Applied Biosystems, Foster City, CA,
USA). The qRT-PCR was performed for MITF, SOX5 or
SOX10 as the gene of interest (GOI) and glyceraldehyde-
3-phosphate dehydrogenase (GAPDH) as the housekeep-
ing gene (HK) using the TaqMan probes HS01117294_m1
MITF, HS00753050_s1 SOX5, HS00366918_m1 SOX10
(Life Technologies, Carlsbad, CA, USA) and HuGAPDH
(Applied Biosystems, Foster City, CA, USA), respectively.
The qRT-PCRs were run on an Applied Biosystems 7300
Real Time PCR system. For all samples, three technical
replicates were performed for both MITF and GAPDH.
Median Ct values for MITF and GAPDH were calculated
based on three technical replicates for the different sam-
ples. ΔCt values were calculated according to
ΔCt ¼ CtMITF−CtGAPDH ð5Þ
to normalize the MITF level to the control (GAPDH).
ΔΔCt values were calculated according to
ΔΔCt ¼ Cttransfected−Ctcontrol ð6Þ
to normalize the sample transfected with siRNA against
SOX5 or SOX10 mRNA to the control condition. Finally,
the fold change was calculated according to
Foldchange ¼ 2−ΔΔCt ð7Þ
MITF-promoter reporter assay
Stable transfection of MaMel-122 cells was performed
to generate a cell line that expresses the green fluor-
escence protein (GFP) gene downstream of the MITF
promoter.
The human MITF promoter was amplified from the
plasmid pMI, kindly provided by Dr. Ballotti [28], with
the following primers:
MITF prom forward→CGCATCGATAGGCCGTTAG
AAACATGATC
MITF prom reverse→CGCTCTAGACAATCCAGTG
AGAGACGGTAG
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GFP Puro (pLenti CMV GFP Puro (658-5) was a gift from
Eric Campeau; Addgene plasmid # 17448) [29]. For this
purpose, the CMV promoter was cut from pLenti CMV
GFP Puro with ClaI and XbaI and the MITF promoter
was introduced at the same position. A plasmid map of
the used vector MITFP-pLenti can be found in the supple-
ment (Additional file 1: Figure S2). Functional validation
of the vector was performed in primary human melano-
cytes in comparison to human fibroblasts (Additional file
1: Figure S3). Melanocytes and fibroblasts were isolated
following standard protocols from skin remainings after
operations such as foreskins after circumcisions of healthy
donors. Successfully MITFP-pLenti transfected cells were
positively selected using 0.5 μg/ml puromycin.
The generated cell line was denoted by MaMel-122-
pMITF and was constantly kept under selective pressure.
MaMel-122-pMITF was used to investigate the role of
SOX10 and SOX5 in regulating MITF at the transcrip-
tional level. siRNA transfection experiments were per-
formed analogous to the qRT-PCR analyses. 1 · 105 cells
were seeded in 24-well plates and cultured for 24 h.
Then, the wells were transfected with either SOX10
siRNA, SOX5 siRNA, non-targeting control siRNA or a
mixture of both, i.e. SOX10 and SOX5 siRNA. The final
concentration of each siRNA per well was 25 nM. The
cells were harvested 72 h after transfection. The cells were
detached from each well with 50 μl trypsin and resus-
pended in 150 μl of medium. After centrifugation, the cell
pellets were washed once with 200 μl PBS and three times
with 1 ml ice cold FACS buffer. Finally, the pellets were
dissolved in 200 μl FACS-buffer and fluorescence mea-
surements were performed using a BD FACSCaliburTM
(BD Biosciences) flow cytometer using channel FL-1 to
detect GFP. Unstained MaMel-122 cells were included in
each individual measurement as a negative control. The
analysis of the flow cytometry data was conducted using
FlowJo version 9.6.4 (http://www.flowjo.com/).
Proliferation assay
The effect of SOX5 on cell viability was assessed using
CellTiter-Glo Luminescent Cell Viability Assay (Pro-
mega, Fitchburg, WI, USA) after transfection with 10
nM control or SOX5 siRNA pools. 1 x 104 cells (fast
growing) and 2 x 104 cells (slow growing) cells were
seeded per well in 96 well black/clear flat bottom plates
(Corning, Corning NY). Viability was measured accord-
ing to the manufactures instructions 24, 48 and 72 h
after transfection. Three biological replicates were per-
formed for each condition.
Invasion assay
Invasion assays were performed 48 h after transfection
with SOX5 or control siRNA pool (10 nM) in 24 wellplate format. Therefore, 5 x 104 cells resuspended in
50 μl serum-free medium (three technical replicates)
were pipetted into the upper insert of a 96 well transwell
plate (Corning, Corning NY) coated with 50 ng matri-
gel/well. The lower chambers were filled with 150 μl
medium + 10 % FCS as a chemoattractant. After 24 h,
invaded cells were detached from the membrane,
washed, stained with calcein AM (Thermo Fisher Scien-
tific, Waltham, MA) and analyzed with a fluorometer ac-
cording to the manufactures protocol.
Statistical analysis
Statistical significance was calculated using the one-
sided two-sample Student’s t-test and a Wilcoxon rank
sum test was performed for non-normally distributed
populations (comparing the distribution of SOX5 expres-
sion between different subgroups of SKCM data (sur-
vived vs. non-survived, thin vs. thick)). P-values less than
0.05 were considered statistically significant. For the
Kaplan-Meier analysis the cutoffs for low and high ex-
pression were determined by a 10-fold cross-validation
approach using the R-package maxstat [30]. The median
cutoff was used to classify samples into low and high ex-
pression subgroups and nonparametric log-rank tests
were used to assess significance. All statistical analyses
were performed using R version 3.0.1 (http://www.r-pro-
ject.org/) and Microsoft Excel 2013.
Prediction of Breslow thickness
A linear model consisting of the expression for the three
transcription factors SOX5, MITF and SOX10 was opti-
mized by minimizing the differences between measured
Breslow thickness tj for sample j and predicted Breslow
thickness tje via minimizing the sum of error terms ej:
Xl
j¼1 ∣tj−
~t j∣ ¼
Xl
j¼1ej ð8Þ
The Breslow thickness was predicted for melanoma
patient sample j using the linear model
tj ¼ β0 þ βSOX5⋅ef f SOX5; j þ βSOX10⋅ef f SOX10; j
þ βMITF ⋅ef f MITF ; j ð9Þ
with β0 as an additive offset, βTF as the optimization par-
ameter for the TF (SOX5/SOX10/MITF) and effTF,j as
the estimated effect of a TF in sample j. As effect effTf,j,
we used the gene expression of the TF in sample j.
Results
The workflow
The workflow is depicted in Fig. 1. First, we selected all in-
formation on transcription factors binding to the MITF
promoter from several databases and from an analysis of
position weight matrices. The resulting transcription
Fig. 1 (See legend on next page.)
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Fig. 1 Workflow. We used a regression approach (based on Mixed Integer Linear Programming, MILP) to design a gene regulatory network
model. The model aimed to predict MITF expression in order to find the regulators that best explain changes in MITF expression levels across
different cell lines. For this, we used transcription factors known to bind at the promoter of MITF extracted from databases and the literature.
After this, we performed wet-lab experiments, the effects of the predicted transcription factors (SOX5 and SOX10) were validated using transfection
assays with siRNA against these transcription factors and MITF-promoter reporter assays. Finally, the clinical impact of MITF and its regulating transcription
factors (SOX5, SOX10) was analyzed by investigating expression levels within melanoma tumor samples according to different clinically
relevant parameters (non-survival versus survival; thin versus thick tumors)
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vestigated cancer cell samples. A regression model was
constructed using mixed integer linear programming
(MILP). The MILP models were trained with training sets
using a calculated sample specific activity of each of the
putative transcription factors to predict the transcript
levels of MITF. The trained models were applied to a val-
idation set and the prediction performance calculated
(Pearson correlation between predicted and measured
gene expression of each sample). Models were built with
an increasing number of included transcription factors in
each round, starting with one transcription factor up to all
candidate transcription factors. In each round, the MILP
model selected the optimal set of regulators. Performing
this within several iterations and a cross-validation scheme,
the best performing transcription factors were selected
(SOX5 and SOX10). Their regulatory effect on MITF ex-
pression was experimentally validated measuring MITF ex-
pression of SOX5 and SOX10 knockdowns and by an
MITF promoter reporter assay. Finally, the clinical implica-
tions were investigated by comparing the expression pro-
files of SOX5, SOX10 and MITF to clinically relevant
parameters (overall survival and tumor stage), leading to a
biomarker regression model (of SOX5, SOX10 and MITF).
Identifying the regulators of MITF in silico
The first task was to identify TFs that best explain MITF
expression. To identify MITF regulators distinctively and
differentially active in melanoma cells, we investigated
the expression dataset of the NCI-60 panel comprised
not only of melanoma cells but also of cells from several
other tumor entities. A list of the summarized results of
the bottom-up procedure can be found in Table 1. The
first regulator selected by the model was SOX5. A model
consisting of SOX5 alone had a very good prediction
performance with a Pearson correlation of r = 0.83
(modeled gene expression of MITF versus measured
gene expression of the microarrays). In addition, correl-
ation of our activity parameter actj,t for TF t in cell line j
with MITF expression levels gj,MITF revealed SOX5 as
the top-correlating regulator with Pearson Correlation
Coefficient (PCC) r = 0.85 (a list of correlations for all
investigated TFs is given in Additional file 1: Table S1).
Also, SOX10 showed a very good performance in the
model (PCC r = 0.73) and also its activity correlated verywell with MITF expression (PCC r = 0.73). We wanted
to know how well the two transcription factors SOX5
and SOX10, taken together, can explain the expression
of MITF. Hence, we constructed a linear regulation
model consisting of SOX5 and SOX10. This model
showed very good performance for predicting MITF ex-
pression levels for the NCI-60 cell lines with an average
PCC of r = 0.83. Furthermore, hierarchical cluster ana-
lysis (average linkage and Euclidean distance) showed
that SOX5 and SOX10 expression is sufficient to clearly
distinguish melanoma from other cancer types. Nine out
of 10 melanoma samples clustered together (Additional
file 1: Figure S4). MITF is often referred to as the master
regulator of melanocytes and melanoma cells and it is
not surprising that it is differentially expressed in melan-
oma cell lines compared to cells from other cancer types
(significance of differential expression of MITF: p = 2E-5).
Interestingly, also SOX5 (p = 0.0008) and SOX10 (p = 3E-6)
showed a significantly higher expression in melanoma
samples compared to all other cells (Fig. 2). Furthermore,
we wanted to confirm computationally that SOX5 and
SOX10 are regulators of MITF expression in melanoma
cells and thus analyzed a dataset of melanoma cells only.
We repeated this analysis with a publicly available melan-
oma cell line set described by Hoek et al. [16, 17]. Consist-
ently, SOX5 and SOX10 exhibited the best correlations of
the activity and the gene expression of MITF (PCC r = 0.75
and r = 0.69). Performing the modeling, SOX5 was again
the selected TF that could alone predict MITF expression
best. Strikingly, we obtained very good prediction results
(PCC r = 0.76) by using the optimization parameters of the
SOX5/SOX10 model learned on the NCI-60 data for the
prediction of MITF levels of the independent melanoma
data set (33 melanoma samples).
The regulatory network model and the estimated ac-
tivity values revealed SOX5 and SOX10 as important
regulators of MITF. In agreement with our findings,
SOX10 is a commonly known activating regulator of
MITF [18, 31] in human. MITF regulation by SOX5 has
only been shown in murine cells so far [32] and hence
we were interested in the regulatory effect of SOX5 on
MITF in human melanoma cells and tumors, and its
regulatory effect in combination with SOX10. Thus, we
performed functional assays to validate our in silico pre-
dictions in human melanoma cells and investigated the
Fig. 2 Expression of SOX5, MITF and SOX10 in 59 cell lines of the National Cancer Institute (NCI-60 panel). The expression of SOX5, MITF and
SOX10 was compared between melanoma samples in the NCI-60 panel and the remaining cancer types. All three genes showed significantly
higher expression in melanoma cell lines. Statistical significance was determined by two-sided two-sample Student’s t-tests. ***p < 0.001;
****p < 0.0001
Table 1 Results of the bottom-up approach for modeling MITF regulation using Mixed Integer Linear Programming
No. of
TFs
Predicted TFs Performance*
1 SOX5 0.83
2 ESR2, SOX5 0.87
3 ESR2, PAX2, SOX5 0.88
4 ESR2, NFKB1.1, PAX2, SOX5 0.89
5 ESR2, NFKB1.1, PAX2, SOX5, ZEB1 0.90
6 ESR2, NFKB1.1, ONECUT2, POU3F2, SOX5, ZEB1 0.91
7 ESR2, NFKB1.1, ONECUT2, PAX2, POU3F2, SOX5, ZEB1 0.91
8 ESR2, GLI2, NFKB1.1, ONECUT2, PAX3, POU3F2, SOX5, ZEB1 0.91
9 ESR2, GLI2, NFKB1.1, ONECUT2, PAX2, PAX3, POU3F2, SOX5, ZEB1 0.90
10 ESR2, GLI2, IRF1, NFKB1.1, ONECUT2, PAX2, PAX3, POU3F2,SOX5, ZEB1 0.92
11 BHLHE40, ESR2, GLI2, IRF1, NFKB1.1, ONECUT2, PAX2, PAX3, POU3F2, SOX5, ZEB1 0.92
12 ESR2, LEF1, NFKB1.1, ONECUT2, PAX2, PAX3, PAX6, PDX1,POU3F2, SOX5, SOX9, ZEB1 0.92
13 ESR2, LEF1, NFKB1.1, ONECUT2, PAX2, PAX3, PAX6, PDX1,POU3F2, SOX5, SOX9, TCF4, ZEB1 0.91
14 BHLHE40, ESR2, LEF1, NFKB1.1, ONECUT2, PAX2, PAX3, PAX6, PDX1, POU3F2, SOX5, SOX9, TCF4, ZEB1 0.91
15 BHLHE40, ESR2, GLI2, LEF1, NFKB1.1, ONECUT2, PAX2, PAX3, PAX6, PDX1, POU3F2, SOX5, SOX9, TCF4, ZEB1 0.90
16 BHLHE40, ESR2, GLI2, LEF1, NFKB1.1, ONECUT2, PAX2, PAX3, PAX6, PDX1, POU3F2, SOX10, SOX5, SOX9, TCF4, ZEB1 0.89
17 BHLHE40, ESR2, GLI2, LEF1, NFKB1.1, ONECUT2, PAX2, PAX3, PAX6, PDX1, POU3F2, SOX10, SOX2, SOX5, SOX9, TCF4, ZEB1 0.89
18 BHLHE40, ESR2, GLI2, IRF1, LEF1, NFKB1.1, ONECUT2, PAX2, PAX3, PAX6, PDX1, POU3F2, SOX10, SOX2, SOX5, SOX9, TCF4, ZEB1 0.87
19 BHLHE40, CREB1, ESR2, GLI2, IRF1, LEF1, NFKB1.1, ONECUT2, PAX2, PAX3, PAX6, PDX1, POU3F2, SOX10, SOX2, SOX5, SOX9, TCF4, ZEB1 0.86
*Averaged Pearson correlation of the model from the training data compared to the validation data
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spect to clinically relevant parameters.
Experimental validation
SOX10 and SOX5 were individually knocked down by
siRNA transfection experiments and significant changes
of MITF levels were detected by qRT-PCR (Fig. 3). In all
three tested melanoma cell lines (MaMel-61e, MaMel-
122 and MaMel-86b) the knockdown of SOX5 resulted
in significantly increased MITF levels compared to cells
transfected with control siRNA. In contrast, knockdown
of SOX10 resulted in significantly decreased MITF levels
in all three cell lines. This is in line with the reported
observation that SOX10 is an activator of MITF [18, 31,
32]. For MaMel-86b the MITF level was about 3.5 times
lower in the SOX10 siRNA transfected sample compared
to the control. To verify the effect of SOX5 knockdown
on MITF levels, we repeated the transfection experiments
with siRNA pools. These pools consisted of 30 individual
siRNAs which strongly decrease off-target effects [27]. We
estimated the SOX5 and SOX10 knockdown efficiency via
qRT-PCR and observed a knock-down efficiency of 50–
60 % (Additional file 1: Figure S5). The effect on MITF ex-
pression levels was confirmed: in all three cell lines, MITF
levels were significantly increased after SOX5 knockdown
compared to control pool transfections (Fig. 3).Fig. 3 Change in MITF expression 48 h after siRNA transfection. The melan
with (a) 25 nM SOX5 siRNA s13303 or (b) 25 nM SOX10 siRNA s13308. MITF ex
and control siRNA transfected cells. Graphs show the mean expression and st
significant increase in MITF expression in all three cell lines, whereas knockdow
MITF expression significantly decreased after SOX10 knockdown. At least four
verify the effect, the transfections were repeated with SOX5 siRNA pool and c
For all three investigated cell lines, the increase in MITF expression after SOX5We validated these results with a promoter-reporter
assay using MaMel-122-pMITF cells, which were stably
transfected with a GFP reporter containing an MITF
promoter. Again, knockdown of SOX10 resulted in a sig-
nificantly reduced reporter (GFP fluorescence) signal (p
= 0.007) compared to the control reflecting lowered
MITF promoter activity. In contrast, knockdown of
SOX5 resulted in a significantly increased reporter signal
(p = 0.022) compared to the control reflecting increased
MITF promoter activity. Furthermore, a combined
knockdown of SOX10 and SOX5 was investigated. As
expected, we observed a rescue effect: the reporter signal
was increased compared to exclusively knocking down
SOX10 (p = 0.031) (Fig. 4). In summary, we could con-
firm our computational predictions, i.e. SOX5 is indu-
cing and SOX10 is repressing MITF expression in the
observed melanoma cells.
Phenotypic effects of SOX5 knockdown
To analyze the effects of SOX5 knockdown on viability
and invasion we transfected five melanoma cell lines
with SOX5 siRNA or control siRNA pools. Viability of
SOX5 siRNA transfected cells was assessed 24, 48 and
72 h post transfection and compared to the controls. A
decreased proliferation rate was observed in all SOX5
siRNA transfected melanoma cells, except for one celloma cell lines MaMel-122, MaMel-86b and MaMel-61e were transfected
pression was measured by qRT-PCR, normalized to GAPDH expression
andard deviation of fold changes. Knockdown of SOX5 resulted in a
n of SOX10 led to diminished MITF expression. In all three cell lines, the
independent biological replicates were performed for each condition. To
ontrol siRNA pool (10 nM) (c) with four biological replicates per condition.
knockdown could be confirmed
Fig. 4 GFP fluorescence of MaMel-122-pMITF cells 72 h post-siRNA transfection. The mean fluorescence of the GFP reporter gene was calculated
based on all investigated cell lines. All samples were compared to the control condition and unstained MaMel-122 cells were used as the negative
control. For each condition, two biological replicates were performed. Statistical significance was determined by two-sided Student’s t-tests.
*p < 0.05; **p < 0.005
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S6). The effect of SOX5 knockdown on invasion was
assessed by the Boyden chamber invasion assay after
transfection with SOX5 or control siRNA pools. We ob-
served a reduced invasive behavior in the strongly invading
cell lines MaMel-122, MaMel-86b and A375. In contrast,
the poorly invading cell lines MaMel-61 and MaMel-79b
did not show a reduction in invasion after SOX5 knock-
down (see Table 2, Additional file 1: Figure S7).
Clinical impact
Having confirmed the involvement of SOX5 and SOX10
in MITF regulation experimentally, we wanted to unravel
the clinical impact of this regulatory network using the ex-
pression data of melanoma tumor samples obtained fromTable 2 Effects of SOX5 siRNA on cell viability and invasion
Cell line Proliferation Invasion
24 h 48 h 72 h 24 h
A375 1.26 1.17 0.99 0.77 (*)
MaMel-79b 0.97 0.91 (*) 0.84 (***) 1.09
MaMel-61e 0.90 0.95 0.79 (***) 1.15
MaMel-122 0.90 0.89 (***) 0.82 (***) 0.87 (*)
MaMel-86b 0.81 (*) 0.82 (*) 0.93 0.62 (*)
Numbers give ratios of SOX5 to control siRNA pool transfected samples.
Assays were performed at the indicated time points after transfection.
*P-value < 0.05 and ***P-value < 0.0005The Cancer Genome Atlas (SKCM, Skin Cutaneous
Melanoma, http://cancergenome.nih.gov/). Overall, 352
samples of SKCM were used for the analysis. We per-
formed a cross-validation based Kaplan-Meier analysis
(see Methods) and determined the optimal cutoff of SOX5
expression as -0.5958 with better survival for the subgroup
with a SOX5 expression equal or higher than -0.5958
(Fig. 5). The discrimination of patients considering MITF
or SOX10 expression did not reveal a significant difference
of survival. Furthermore, we compared the expression
levels between the subgroups of primary melanoma (69
samples) and distant metastasis (39 samples). Only for
SOX5 expression, a clear tendency (p = 0.06) between the
subgroups of primary tumor and metastases samples
could be observed with a differential down-regulation of
SOX5 in primary samples, when compared to metastatic
samples (see Additional file 1: Figure S8). In summary,
higher SOX5 expression was associated with a better clin-
ical course of melanoma patients; we thus further studied
the clinical relevance of SOX5 expression investigating the
Breslow thickness of primary melanoma tumors.
The Breslow thickness resembles the thickness of the
primary tumor of local melanomas and is used to clas-
sify melanoma into different tumor stages (T1 - T4).
The Breslow thickness is negatively correlated with over-
all survival and can be used to categorize patients into
subgroups [2, 33]. Here, we have analyzed a possible as-
sociation of Breslow thickness with SOX5, SOX10 and
Fig. 5 Survival analysis. The SKCM samples were divided based on
their SOX5 expression and based on their survival times (days to
death). Kaplan-Meier plot was generated. A significant difference of
the two survival distributions could be observed (p = 0.0006; log-rank
test) with an improved survival rate for the subgroup with higher
SOX5 expression (≥-0.5958)
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ing approach. To test for such an association, we investi-
gated, if SOX5, SOX10 and MITF can be used to predict
Breslow thickness. The prediction was performed for
266 samples from the SKCM data set with available Bre-
slow thickness and gene expression data. However, the
estimated prediction performance (based on a leave one
out cross validation for all samples) was very poor (PCC
r = 0.02). Previous studies showed that the Breslow
thickness provides more prognostic information if cut
points are used [34]. In line, we divided the samples into
subsets according to their Breslow thickness used for the
classification of the tumor staging (T1-T4). This im-
proved the performance considerably, in particular for
the group of tumors with thin thickness (Table 3). Good
or reduced prediction performance was obtained for
melanoma with thin (<=1 mm; r = 0.53, n = 39) and
intermediate thickness (>1 and <4 mm; r = 0.24; n =
125), respectively. In contrast, prediction for thick tu-
mors showed no significant correlation with thickness
(>4 mm; r = 0.07; n = 102). As expected, survival times of
our investigated tumor samples with a small BreslowTable 3 Prediction of Breslow thickness for SKCM melanoma
samples using the regression model of SOX5/MITF/SOX10
Group Thickness Number of samples PCC r*
All samples - 266 0.02
Thin < 1 mm 39 0.53
Intermediate 1 – 4 mm 125 0.24
Thick > 4 mm 102 0.07
*Pearson correlation of the model from the training data compared to the
validation datathickness (<1 mm) was significantly higher (p = 0.005)
than the remaining samples.
To understand the observed differences in prediction
performance between subgroups with thin and thick tu-
mors, we investigated the expression distributions of
SOX5, SOX10 and MITF. Interestingly, we observed a bi-
modal distribution of SOX5 expression. Figure 6 shows
the density function of SOX5 expression of all investi-
gated SKCM samples with the vital status dead pointing
to a bivalent role of SOX5. The corresponding histogram
and the density function for the subgroup with thick tu-
mors is presented in Additional file 1: Figures S9 and
S10, respectively. Also for the investigated 33 melanoma
cell lines from the Mannheim cohort [17] which only in-
cluded samples from stage III and IV melanoma pa-
tients, SOX5 expression followed a bimodal distribution,
as shown in Additional file 1: Figure S11.
High percentages of melanoma tumor cells show mu-
tations in the BRAF locus [35] Due to the fact, that in
melanoma hyper-activated BRAF often suppresses MITF
[13–17], we compared the BRAF mutation status with
the expression of MITF, SOX10 and SOX5. Investigating
the SKCM dataset, SOX10 and MITF expression tended
to be higher in melanoma samples with normal BRAF
(p = 0.06 and p = 0.08, two sided Student’s T-test). Strik-
ingly, SOX5 was significantly overexpressed in samples
with mutated BRAF (p = 0.006). We observed a weakly
positive correlation of SOX5 and MITF expression in
the BRAF wildtype subgroup (Pearson’s correlation r =
0.18), and weakly negative correlation in the BRAF mu-
tated subgroup (PCC r = -0.13) hinting for a stronger
regulatory involvement of SOX5 on MITF expression in
the tumor cells with BRAF mutation. Comparing tumor
subgroups of NRAS mutated with NRAS wildtype, noFig. 6 Distribution of SOX5 expression in the SKCM dataset with vital
status dead
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SOX5 which was significantly overexpressed in NRAS
mutated samples (p = 0.05). Taken together, SOX5,
SOX10 and MITF seem to have a crucial clinical impact
and our developed linear regression based expression
signature of these three genes associated in particular
with melanomas with a small Breslow thickness.
Discussion
In this study, a transcription factor network was con-
structed based on chromatin immunoprecipitation bind-
ing data from several data repositories and a motif
analysis. Using our established regression model (MILP
model) and the defined activity, we found the transcrip-
tion factors SOX5 and SOX10 with which the model
could predict best the gene expression values of MITF in
various melanoma cell lines. Indeed, both transcription
factors were capable to explain the differences in MITF
expression levels when trained with a dataset of cells
from different tumors and applied to a different dataset,
i.e. a dataset of melanoma cell lines. In particular, SOX5
was found to be a very informative predictor, exhibiting
the highest correlation of its calculated activity with
MITF expression. We confirmed experimentally that
SOX5 and SOX10 have an effect on MITF expression
levels in melanoma cell lines; SOX5 down-regulation in-
creases MITF expression, hinting at an inhibitory effect,
while vice versa, SOX10 down-regulation led to MITF
up-regulation. In addition, our model predicted a com-
bined regulation in which MITF transcription is acti-
vated by SOX10 and inhibited by SOX5. In line with
this, after investigating the expression profiles of the
melanoma cell lines (Mannheim cohort of [17]), we ob-
served a correlation between SOX5 and SOX10 expres-
sion (PCC r = 0.43) and an even stronger correlation
between the activity of SOX5 and SOX10 (PCC r = 0.75).
SOX10 is a well-known transcriptional activator of
MITF [18, 31]. In addition to this, we found SOX5 to be
a novel regulator of MITF in human melanoma cells.
Stolt and coworkers found the involvement of SOX5 in
melanocyte development by altering SOX10 activity in
mouse models. In mice, SOX5 and SOX10 can bind to
the same locus on their target genes Mitf and Dct. It was
shown in B16 mouse melanoma cells that SOX5 pre-
vents the activation of these target genes through site
competition with SOX10 [32, 36]. We observed a similar
effect in human melanoma cells: A double knockdown
of SOX5 and SOX10 partially rescued MITF expression
compared to a single knockdown of SOX10. We assume
that SOX5 regulates MITF via direct binding to the
MITF promoter as (i) Stolt and coworkers showed in
mice [32], and (ii) as we observed a strong binding pro-
file of the sequence motif in SOX5 to the MITF
promoter (see Additional file 1: Figure S1 in thesupplementary material); however direct binding re-
mains to be shown with e.g. ChIP experiments.
In addition to SOX5 and SOX10, to a lesser extent,
also SOX2 and SOX9 were among our predicted candi-
dates of selected transcription factors (in the models
with 12 or more predicted regulators, see Table 1). It is
known, that also other SOX family members are in-
volved in melanocyte development [36]. Shakova and co-
workers observed an efficient reduction of tumorigenesis
in animal models and in human melanoma cells when
reducing SOX10 expression levels and for this anti-
tumoric effect they found SOX9 to be required as a
functional antagonistic regulator of SOX10 [37]. Besides
this, Liu and Lefebvre found that the regulatory trio of
SOX9, SOX5 and SOX6 cooperatively work together to
activate super-enhancers in a genome-wide way in rat
chondrosarcoma cells [38]. Taken together, these obser-
vations are in line with our observation that SOX5 and
SOX10 have an opposing effect on regulation of the cen-
tral transcription factor MITF. When investigating the
SKCM dataset, we found SOX9, SOX2 as well as SOX6
to be down-regulated in the tumor subgroup of low
SOX5 expression compared to the tumor subgroup of
high SOX5 expression (see Additional file 1: Table S2).
For the future, it could be intriguing to disentangle the
fine grained interplay between these SOX family mem-
bers and their involvement in tumor progression. The
analysis of clinical tumor data (SKCM) revealed that
higher SOX5 expression was a significant indicator for
longer survival (Fig. 5). Accordingly, we observed a ten-
dency towards longer survival of patients with tumors
showing lower expression of MITF (Additional file 1:
Figure S12).
We observed a higher SOX5 expression in metastatic
melanoma compared to primary melanoma (Additional
file 1: Figure S8), although the survival analysis revealed
that very low SOX5 expression is associated with poor
prognosis (Fig. 5). This might point towards a dual func-
tional role of SOX5 depending on primary versus meta-
static tumor stage. We speculate that SOX5 could be an
important factor during the transition from primary to
metastatic melanoma, as SOX5 knockdown resulted in
reduced invasion (Table 2). As only ten primary melan-
oma samples from patients who succumbed to disease
were available, we performed a correlation analysis on
SOX5 expression and survival time resulting in a strongly
negative (r = -0.65) correlation, whereas in metastatic mel-
anoma samples only a weak correlation could be observed
(r = -0.12; not shown). This is in line with Riker et al., who
observed in their analyses that SOX5 expression is
strongly increased in thick versus intermediate melanoma
samples (Breslow’s thickness), associated with onset of
metastatic phenotype [39]. In contrast, our survival ana-
lysis revealed a worse prognosis for patients with tumors
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cluded mainly metastatic tumor samples and only ten
samples from primary tumors. We speculate that in meta-
static melanoma the anti-proliferative effect of very low
SOX5 and thus high MITF levels might lead to a dimin-
ished susceptibility to chemotherapy and thus to a worse
prognosis.
Regulation of MITF expression is highly complex and
mediated by various activating and inhibiting intra- and
extracellular processes. Although high MITF levels have
an anti-proliferative effect, MITF expression is detect-
able in almost all melanoma tumors. It seems that a
basal level of MITF expression is necessary for melan-
oma cells and therefore MITF expression and activity is
not entirely down-regulated, which is in line with the
observation that almost all melanoma cells maintain
their ability to synthesize melanin. Wellbrock and co-
workers proposed that a low basal MITF level could be
important for the survival of melanoma cells and also
for their proliferation through regulation of cyclin-
dependent kinase 2 (CDK2) and B-cell CLL/lymphoma 2
(BCL2) [40]. They proposed that an intermediate, well-
balanced MITF level is important for melanoma cells to
survive and proliferate. We add to this the notion that a
well-tuned interplay of SOX5 and SOX10 could be cru-
cial for this homeostasis of MITF expression, avoiding
too high as well as too low MITF expression.
We found that up-regulation of SOX5 expression co-
occurs with BRAF mutations. It might be favorable for
the tumor to suppress MITF expression with different
strategies like increased BRAF activity that leads to
MITF degradation, or increased inhibition of MITF tran-
scription due to SOX5 blocking the binding site of
SOX10. In future studies, it would be interesting to in-
vestigate whether increased SOX5 expression is a down-
stream effect of BRAF mutation or whether it is rather
an independent control mechanism for MITF regulation.
Interestingly, the prediction of Breslow thickness using
all of the investigated regulators (SOX5, SOX10, and
MITF) showed good prediction performance only for
thin melanoma tumors (<1 mm) and was rather poor for
thick melanomas. This may indicate a transition point in
melanoma progression. Indeed, Riker and coworkers re-
ported of a transition point of melanoma progression;
they observed that most genes up-regulated in more ad-
vanced melanoma exhibit the highest change of their ex-
pression level during the transition of intermediate to
thick lesions [39]. We also observed a similar transition
by modeling Breslow thickness with the three TFs,
SOX5, SOX10 and MITF. Interestingly, we identified a
bimodal distribution of SOX5 expression in tumor sam-
ples and also in the melanoma cell lines. Cells of a po-
tential subset of melanoma, which is indicated by the
bimodal distribution, may use the up-regulation ofSOX5 to repress MITF in order to prevent its inhibitory
effect on proliferation.
Conclusions
To conclude, we applied a computational approach to
infer transcriptional regulation of MITF in human mel-
anoma cells employing microarray expression profiles.
Besides SOX10, we identified SOX5 regulating MITF in
human melanoma cells and validated its inhibitory effect
experimentally by functional and reporter assays. We
found low SOX5 expression to be an indicator for
shorter survival of patients with melanoma tumors. In
the future, SOX5 might play an important role when en-
tangling the fine grained interplay of MITF regulation
and its impact on tumorigenesis. SOX5 may suit as a
prognostic marker in combination with other bio-
markers involved in regulation of MITF.
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